Prognostic factors in first-line atezolizumab-bevacizumab treatment of intermediate or advanced hepatocellular carcinoma. Gu K, Kang TW, Shin J, Sinn DH, et al. PLoS One 2026;21:e0354176.

Read + Share

Amedeo Smart

Independent Medical Education

Read + Share

Gu K, Kang TW, Shin J, Sinn DH, et al. Prognostic factors in first-line atezolizumab-bevacizumab treatment of intermediate or advanced hepatocellular carcinoma. PLoS One 2026;21:e0354176.
PMID: 42520023